Clinical Trial Search

Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Overall Response Rate (ORR) — 50 percentage of participants

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Biochemical Response Rate — 0 participants

Primary: Duration of NHT Treatment — 11.9 Months

Primary: Progression Free Survival — 16.1 months

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Number of Participants With PSA Remission Assessed Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria — 29; 16 Participants

Primary: Metabolic Syndrome — 0; 0 kilograms

Primary: Progression-free Survival — 13 months

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Radiographic Progression-Free Survival (PFS) — 33.02; 14.78 Months — p=<0.0001

Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16

Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants

Primary: Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2)…

Primary: Maximum Tolerated Dose (MTD) of Pasireotide in Combination With Docetaxel and Prednisone by the Occurrence of Adverse Events and the Associated Grade Per NCI Common…

Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants

Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants

Primary: PSA Progression-free Survival — 20.8; 16.5 Months — p=0.83

Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Overall Survival — 87; 86 percentage of probability of survival — p=0.70